Centrus Energy Corp vs Smith & Nephew plc — how do they compare? Centrus Energy Corp trades at $142.44 (market cap $2.91B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3.8× Centrus Energy Corp's market cap, and Smith & Nephew plc pays a 2.95% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Smith & Nephew plc for 121 Days on average.
| LEU | SNN | |
|---|---|---|
Market Cap | $2.91B | $11.10B |
Volume | 903,777 | 1,051,703 |
Sector | Energy | Health |
52-Week High | $436.00 | $37.17 |
52-Week Low | $138.18 | $26.42 |
Typical Hold Time | 29 Days | 121 Days |
Enterprise Value | $2.22B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $142.09, down 3.43% on the day, with technical indicators showing a bearish trend. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights Centrus as a key player in the nuclear fuel supply chain, securing multiple HALEU contracts amid growing nuclear energy demand. Valuation metrics appear elevated with a P/E of 75.18 and P/S of 6.68, while profitability metrics show a net income margin of 10.23% and ROE of 8.05%.
The outlook for LEU is cautiously optimistic, supported by strategic positioning in the nuclear fuel market and recent contract wins. However, high valuation multiples and recent earnings volatility present risks. Analyst consensus is mixed with 46% buy ratings and a $218.10 price target, suggesting potential upside if execution improves. Key risks include execution challenges, competitive pressures, and dependence on nuclear energy policy support.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →